Touyun Biotech (01332) is pleased to see a year-on-year increase of about 1025% to 1150% of total profit and overall revenue attributable to shareholders of about HK$180 million to HK$200 million

Zhitongcaijing · 3d ago

Zhitong Finance App News, Touyun Biotech (01332) announced that the Group expects to obtain about HK$180 million to HK$200 million in total profit and comprehensive revenue due to the Company's owners for the six months ending June 30, 2026, an increase of about HK$16 million to HK$16 million compared to the total profit and overall revenue due to the Company's owners in the same period last year, an increase of about HK$16 million. According to the available data, the expected increase in profit is mainly due to the Group's fair value earnings of about HK$340 million from financial assets (unlisted and listed equity investments) recorded at fair value, while fair value earnings for the six months ended June 30, 2025 were approximately HK$73 million.